NCT05202405View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

March 4, 2022

Study Completion Date

March 4, 2022

Conditions
Hyperlipidemias
Interventions
DRUG

AD-221

AD-221 Oral Tablet

DRUG

AD-221A and AD-221B

AD-221A Oral Tablet + AD-221B Oral Tablet

Trial Locations (1)

Unknown

H+ Yangji Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT05202405 - A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B | Biotech Hunter | Biotech Hunter